| Authors: |
Roncal C; Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, CIMA-University of Navarra, IdiSNA, CIMA Building, Av. Pio XII, 55, 31008 Pamplona, Navarra, Spain.; CIBERCV, Ministry of Economy and Competitiveness, ISCIII, Spain., Martinez de Lizarrondo S; INSERM, UMR-S 919, Serine Proteases and Pathophysiology of the Neurovascular Unit (SP2U), Caen, France., Salicio A; Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, CIMA-University of Navarra, IdiSNA, CIMA Building, Av. Pio XII, 55, 31008 Pamplona, Navarra, Spain., Chevilley A; INSERM, UMR-S 919, Serine Proteases and Pathophysiology of the Neurovascular Unit (SP2U), Caen, France., Rodriguez JA; Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, CIMA-University of Navarra, IdiSNA, CIMA Building, Av. Pio XII, 55, 31008 Pamplona, Navarra, Spain.; CIBERCV, Ministry of Economy and Competitiveness, ISCIII, Spain., Rosell A; Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Couraud PO; Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France., Weksler B; Weill Cornell Medical College, Medicine Division of Hematology/Oncology, New York, NY, USA., Montaner J; Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Vivien D; INSERM, UMR-S 919, Serine Proteases and Pathophysiology of the Neurovascular Unit (SP2U), Caen, France., Páramo JA; Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, CIMA-University of Navarra, IdiSNA, CIMA Building, Av. Pio XII, 55, 31008 Pamplona, Navarra, Spain.; CIBERCV, Ministry of Economy and Competitiveness, ISCIII, Spain., Orbe J; Laboratory of Atherothrombosis, Program of Cardiovascular Diseases, CIMA-University of Navarra, IdiSNA, CIMA Building, Av. Pio XII, 55, 31008 Pamplona, Navarra, Spain.; CIBERCV, Ministry of Economy and Competitiveness, ISCIII, Spain. |
